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Regular Article
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Key Points
• INTERIM treatment affects
cytogenetic and molecular
response, but not the
outcome.
• No patients treated with
INTERIM progressed to
accelerated or blast phase.
We report a study of an alternative treatment schedule of imatinib (IM) in chronic myeloid
leukemia (CML). Seventy-six Philadelphia-positive (Ph1), BCR-ABL–positive patients
aged 65 years or older who had been treated with IM for more than 2 years and who
were in stable complete cytogenetic response (CCgR) and major molecular response
(MMR) were enrolled in a single-arm study to test the effects of a policy of intermittent
IM (INTERIM) therapy for 1 month on and 1 month off. With a minimum follow-up of 4
years, 13 patients (17%) lost CCgR and MMR and 14 (18%) lost MMR only. All these
patients resumed continuous IM and all but one (lost to follow-up) regained CCgR and
MMR. No patients progressed to accelerated or blastic phase or developed clonal
chromosomal abnormalities in Ph1 cells or BCR-ABL mutations. In elderly Ph1 CML
patients carefully selected for a stable CCgR (lasting >2 years), the policy of INTERIM treatment affected the markers of residual
disease, but not the clinical outcomes (overall and progression-free survival). This trial was registered at www.clinicaltrials.gov as NCT
00858806. (Blood. 2013;121(26):5138-5144)
Introduction
Over the last decade, the goals of the treatment of Philadelphia
chromosome-positive (Ph1), BCR-ABL–positive chronic myeloid
leukemia (CML) with tyrosine kinase inhibitors (TKIs) have become
more and more ambitious: delayed progression, prolonged survival,
normalization of survival, and treatment discontinuation without
molecular recurrence, or cure.1-6 With imatinib (IM) at the standard
dose of 400 mg/d, 80% to 90% of patients are alive at 8 years, but
only a small proportion of patients (;5%) can discontinue the
treatment without suffering a molecular recurrence.6 Thus, the
great majority of responsive patients would be destined to continue
the treatment indeﬁnitely at the same standard dose. Although
elderly patients have cytogenetic and molecular responses compa-
rable with younger ones, they are less tolerant of IM, and this may
reduce the beneﬁt of therapy by inducing higher rates of therapy
discontinuation and lower adherence to chronic treatment. In this
setting, it may be important to improve tolerability without
impairing the beneﬁt. Because the median age of CML patients at
diagnosis is ;60 years with a life expectancy of ;20 years, it is
particularly important to devise and test age-related policies of
treatment.3,4 Results have been improved by the use of second-
generation TKIs, but their toxicity remains an issue and even if they
prove to be very successful, the majority of patients are expected to
undergo a lifelong treatment.7-12 Although the concept of cure
remains more attractive, it is time to wonder whether the choice
should still be restricted to either “white” (discontinuation) or “black”
(treatment of ever). Therefore, the issue is not only which of these
two policies is better, but also if, between these two extremes (lifelong
treatment vs treatment discontinuation), there are other potential
or possible policies that can be affordable in speciﬁc settings, par-
ticularly in elderly CML patients. One such strategy could be the
identiﬁcation of a schedule of IM that would be sufﬁcient to maintain
response and avoid progression but might improve compliance.
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We report here on a study, the INTERIM study, that was designed
5 years ago to investigate if an alternative policy of treatment,
namely intermittent administration of IM, would affect the surrogate
markers of outcome, namely the cytogenetic and molecular response,
as well as the outcome itself (progression-free survival [PFS] and
overall survival [OS]).
Patients and methods
Patients
Patients with Ph1, BCR-ABL1 CML who were 65 years or older, were
treated with IM frontline, had been on IM for 2 years or longer, and who
were in stable complete cytogenetic response (CCgR) were eligible for
the study. The stability of CCgR had to be documented by negativity of a
chromosome banding analysis (CBA) of at least 20 marrow cell metaphases
within 1 year before enrollment, and again at enrollment. Written informed
consent was requested. The study was conducted in accordance with the
Declaration of Helsinki. The EudraCT protocol number is 2007-005102-
42 and it was approved by the Ethical Committee of the Spedali Civili
Hospital in Brescia, Italy.
From April 2008 to November 2009, 114 Ph1, BCR-ABL1 CML
patients were screened for the study. Nineteen patients (17%) denied consent
and another 19 (17%) were not enrolled either because they had been
pretreated with interferon-a (7 patients) or because the CCgR status was not
conﬁrmed in the baseline sample (12 patients). Seventy-six patients were
enrolled. The main characteristics of these patients are reported in Table 1.
At least 3 of these characteristics are worth noticing: the long duration of
IM treatment, with a median of more than 60 months; the high proportion
(81%) of the patients on a 400-mg dose in spite of the age and the long
treatment duration; and the low proportion of high-risk patients in spite
of the advanced age. The great majority of the patients reported one or
more comorbidities, including cardiovascular in 72% of cases (Table 1).
Also, 71% of patients were taking concomitant medications which in 28%
of the cases were drugs known to be metabolized by the CYP450
isoenzymes, CYP2D6 and CYP3A4.
INTERIM treatment plan
This was a multicenter, phase 2 study (EudraCT no. 2007-005102-42) aimed
to investigate how an intermittent treatment with standard-dose IM would
modify the surrogate markers of outcome, namely the cytogenetic and
molecular response, and how it would affect the treatment outcome,
namely the PFS and OS.
The term “standard imatinib therapy” is used for daily administration of
IM at any dose, whereas “intermittent imatinib treatment” (INTERIM) is used
to deﬁne a treatment where the same dose of IM was given according to the
following intermittent schedule: 1 week on/1 week off for the 1st month
(weeks 1-4); 2 weeks on/2 weeks off for the 2nd and 3rd months (weeks
5-12); 1 month on/1 month off from the 4th month (week 13) to the
12th month and thereafter. The patients who lost the CCgR resumed the
prestudy, daily IM treatment. The patients who lost the major molecular
response (MMR) alone within the ﬁrst year had to continue the
intermittent schedule. After the ﬁrst year, the patients who lost MMR
alone were allowed to go back to the prestudy continuous treatment.
Objectives of the study
The ﬁrst objective of the study was to evaluate the proportion of patients who
remained in CCgR after 1 year on INTERIM. The study was designed 5 years
ago when CCgR was universally recognized as the most solid surrogate
marker of survival.13 Because we anticipated that a proportion of patients
would lose CCgR, all patients were carefully monitored to evaluate if
and when the standard continuous treatment had to be resumed. Other
objectives were to determine the proportion of patients who would lose
MMR, who would lose complete hematologic response, who would develop
BCR-ABL kinase domain (KD) point mutations, and who would progress
to accelerated or blast phase (AP or BP). PFS and OS were calculated for all
patients, with a minimum follow-up of 48 months.
Response monitoring
Clinical evaluation, physical examination, blood counts, and differential,
together with relevant biochemical tests, were performed at the time of
enrollment (baseline) and every 3 months during the study.
Cytogenetics. Karyotypes were performed at each participating center
and were examined after G or Q banding techniques according to the Interna-
tional System for Human Cytogenetic Nomenclature.14 The evaluation of CCgR
was based on CBA of marrow cell metaphases. CCgR was deﬁned as the absence
of the Ph chromosome in at least 20 marrow metaphases. CBA of marrow cell
metaphases was performed at enrollment, then only in the patients who scored
positive by ﬂuorescence in situ hybridization (FISH) during the study.
Interphase FISH analysis of buffy-coat blood cells was performed at
each center every 3 mo during the ﬁrst year (study core) and every 6 months
thereafter. The Locus Speciﬁc Identiﬁer BCR/ABL Dual Color, Dual Fusion
(DF) Translocation Probe (Abbott Molecular-Vysis) or the Double-Fusion
Signal D-FISH BCR/ABL Probe (Oncor-QBiogene) was employed.15 FISH
was deﬁned as either negative or positive if the percent of BCR-ABL–positive
nuclei was <1% or .1%, respectively, counting at least 200 nuclei.15
Therefore, in the patients who became FISH-positive during the study, a
CBA of bone marrow metaphases was performed to conﬁrm the loss of
CCgR and to detect if there were clonal chromosomal abnormalities in Ph1
cells (CCA/Ph1).
BCR-ABL transcript level. Real-time quantitative reverse transcription-
polymerase chain reaction (RT-Q-PCR) for BCR-ABL transcripts was per-
formed at baseline and every 3 months during the study. Samples were collected
at investigational sites and centralized in one of the reference laboratories
Table 1. Main characteristics, comorbidities, and concomitant
medications of the patients who have been enrolled in the INTERIM
study
No. of patients 76
Gender, M/F, n 41/35
Age at enrollment, y, median (range) 72 (65-83)
Patients .80 y old, n (%) 8 (11%)
Time from diagnosis, mo, median (range) 64 (25-98)
Sokal risk (at diagnosis), n (%)
Low (,0.80) 25 (33%)
Intermediate (0.80–1.20) 42 (55%)
High (.1.20) 9 (12%)
IM therapy duration, mo
Median (range) 60 (24-94)
No. of patients with more than 48 mo (%) 51 (67%)
IM dose, mg, median 400
No. of patients at 200 mg (%) 2 (3%)
No. of patients at 300 mg (%) 11 (14%)
No. of patients at 400 mg (%) 62 (81%)
No. of patients at 600 mg (%) 1 (1%)
Patients with comorbidities, n (%) 68 (89%)
Cardiovascular 55 (72%)
Prostatic 14 (18%)
Gastrointestinal 14 (18%)
Kidney 12 (16%)
Arthritis 7 (9%)
Respiratory 6 (8%)
Neurological 6 (8%)
Diabetes mellitus 5 (7%)
Thyroid 5 (7%)
Other 20 (26%)
Patients with concomitant medications, n (%) 54 (71%)
1-2 drugs 20 (26%)
3-4 drugs 24 (31%)
.4 drugs 10 (13%)
Cy3A4 drugs metabolized 21 (28%)
All patients were aged $65 years and were in CCgR for at least 2 years.
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Table 2. Flow diagram of INTERIM study
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(Bologna) of the Gruppo Italiano Malattie Ematologiche dell’Adulto network.
Leukocytes were isolated from 20 mL of peripheral blood after red
blood cell lysis, and RNA was extracted and converted to cDNA according
to conventional methods. RT-Q-PCR was performed with the TaqMan
technology (Applied Biosystems, Foster City, CA) as previously set up and
standardized within the framework of the Europe against Cancer program.16
Results were expressed as the ratio of BCR-ABL/ABL% on the International
Scale17-19 using a laboratory-speciﬁc conversion factor. The conversion factor
was derived by the reference laboratory in Bologna in the framework of the
European Treatment and Outcome Study standardization initiatives.16,19
MMR, corresponding to a 3-log reduction in BCR-ABL transcript level
from the standardized baseline, was thus deﬁned as BCR-ABL <0.1%IS
and is also indicated as MR3.0.
In case of loss of CCgR or MMR, a BCR-ABL KD point mutation
analysis was also performed. The KD of the BCR-ABL transcript was
ampliﬁed by nested RT-PCR and screened by denaturing high performance
liquid chromatography as previously described.20,21
Statistics
Based on previous studies showing that the CCgR rate during continuous
treatment would range between 85% and 95%, and using the optimal Simon’s
2-stage procedure,22 we set p0 (as the proportion of responses below which
the treatment would be considered ineffective) at 85% and p1 (as the
proportion of responses above which the treatment would be considered
effective) at 95%. With an a error of 0.05 and a power 1-b of 80%, the
number of patients to be enrolled was 65. To account for dropouts and
withdrawals, the number of patients was adjusted to 76. The study would
have been stopped if .2 of the ﬁrst 13 patients (15.4%) had lost CCgR
within the ﬁrst year (ﬁrst stage) and .7 of 76 patients (9.2%) had lost CCgR
in the second stage. Standard descriptive statistics, such as mean, median,
range, and proportions, were used to summarize the patient sample. The x2
test was used to compare differences in percentages and the Mann-Whitney U
test was used to compare continuous variables. The Kaplan-Meier method23
was used to estimate PFS, OS, CCgR loss (CBA-positivity), and MMR
(MR3.0) loss from the ﬁrst day on INTERIM. Death by any cause and
progression to AP or BP were the events of interest for PFS. CCgR loss
(CBA-positivity), MMR (MR3.0) loss, and the probability of continuing
INTERIM were calculated using the cumulative incidence procedure.24 Death
was considered the competing risk for CCgR and MMR loss, whereas death
and refusal were the competing risks for the probability of continuing
INTERIM. The Cox proportional hazard regression model was used for
univariate and multivariate analysis of factors associated with CCgR and
MMR loss. The following variables were analyzed: age, sex, Sokal risk
group, baseline BCR-ABL transcript level, and duration of IM therapy before
INTERIM and BCR-ABL transcript level. Variables found to be signiﬁcant at
the P , .10 in univariate analysis were tested in multivariate analysis. All
P values were 2-sided and P , .05 was considered statistically signiﬁcant.
Results
At the time of the start of the INTERIM study, the 76 enrolled
patients were in CCgR and all but one was in MMR (MR3.0).
Table 2 shows the ﬂow diagram of the INTERIM study in which
all the events occurring during the 48 mo of intermittent treatment
with IM are reported.
Thirteen patients (17%) lost CCgR and MMR and all but one
(a patient who was lost to follow-up) regained CCgR and MMR after
they had discontinued INTERIM and resumed continuous IM. The
monitoring and outcome of these patients are detailed in supplemental
Tables 3 and 4. The ﬁrst loss of CCgR (CBA-positivity) was detected
after 6 months. Six patients (8%) lost CCgR during the ﬁrst 12
months and the remaining 7 patients lost CCgR between the 13th
and 27th months. Thus, at 12 and 48 months, the probabilities of
maintaining CCgR were 92% (95% CI: 86% to 98%) and 81%
(95% CI: 71% to 90%), respectively (Figure 1). The loss of MMR
occurred 3 to 9 mo before the loss of CCgR in 9 cases. All 13 patients
discontinued INTERIM and resumed continuous IM treatment at
the same dose and, with the exception of one patient lost to follow-up,
all of them regained the CCgR and MMR after a median of 7 and
6 months from resuming IM daily, respectively; they are still in
chronic phase, in CCgR and in MMR after a median follow-up of
48.5 months (range 39-66) (supplemental Table 3).
Fourteen patients (18%) lost MMR alone. Nine of these dis-
continued INTERIM and resumed daily IM; all regained MMR
(Table 2). The ﬁrst loss of MMR alone was detected after
3 months. Seven patients (9%) lost MMR during the ﬁrst 12
months and the remaining 7 patients lost MMR between the 13th
and 36th month (supplemental Table 4). Thus, at 12 and 48
months, the probabilities of maintaining MMR (MR3.0) were 80%
(95% CI: 71% to 89%) and 63% (95% CI: 52% to 74%),
respectively (Figure 2). The intermittent schedule of treatment was
Figure 1. Probability of maintaining the CCgR on INTERIM. Estimated CCgR
loss was 92% (95% CI: 86-98) at 12 months and 81% (95% CI: 71-90) at 48 months.
Figure 2. Probability of maintaining the MMR on INTERIM. Estimated MMR loss
was 80% (95% CI: 71-89) at 12 mo and 63% (95% CI: 52-74) at 48 mo.
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discontinued in 9 patients who had lost MMR alone; all of these
regained a MMR after a median of 3 months from resuming
daily IM. All 14 patients who lost MMR alone are still in the
chronic phase and in MMR after a median follow-up of 48 months
(range 33-60) (supplemental Table 4).
Age, sex, Sokal risk group, baseline BCR-ABL transcript level,
and duration of IM therapy before INTERIM were not associated
with loss of CCgR or MMR when they were examined by univariate
and multivariate analyses.
One patient developed atrial ﬁbrillation at 15 months and one
refused to continue INTERIM at 24 months, but all the patients
were in CCgR and MMR when the events occurred. No patients
developed CCA in Ph1 cells or BCR-ABL point mutations;
moreover, none of the patients progressed to AP or BP, but 2 died at
24 and 36 months because of acute myocardial infarction and
intracranial hemorrhage, respectively (Table 2). Therefore, the
probabilities of continuing INTERIM were 92% (95% CI: 86% to
98%) and 70% (95% CI: 60% to 80%) at 12 and 48 months,
respectively (Figure 3), and the estimated PFS was 100% at 12
months and 96% (95% CI: 91-100) at 48 months (Figure 4).
No patient complained of new or more severe side effects during
the “on” months. Three patients reported grade 2 side effects
(0 adverse events) at enrolment into INTERIM. In one of these,
ﬂuid retention, muscle cramps, and skin erythema disappeared
after 10 months. In the second patient, skin erythema disappeared
after 8 months. The third patient continued to complain of ﬂuid
retention and skin erythema and this remained stable during
INTERIM. Seventeen patients reported grade 1 side effects at
enrolment in INTERIM (supplemental Table 5). Muscle pain or
cramps and ﬂuid retention disappeared in 4 of 5 patients. Fluid
retention disappeared in 2 of 8 patients. Overall, the side effects
disappeared in 11 of 20 patients (supplemental Table 5).
Discussion
This is a report of a phase 2, single-arm study testing prospectively,
for the ﬁrst time, the effects of a policy of TKI treatment reduction
in patients who were optimal responders to IM but who did not ﬁt
the current requirements for a trial of treatment discontinuation.
The ﬁrst selection was based on age, and the study was limited to
patients who were 65 years or older (the median age was 72 years).
Elderly patients respond to IM as well as young patients,25 but they
have more comorbidities, take more concomitant drugs, and are less
tolerant of TKI. Furthermore, compared with younger patients, elderly
patients may suffer less from living with leukemia, have fewer
problems related to family planning and career, but may have more
ﬁnancial problems in those countries where the cost of TKI cannot
yet be completely covered by a public health system or private
insurance. These reasons can be more or less general, but in many
diseases, treatment is modulated according to age and there are no
good reasons why CML should be an exception.
The schedule of 1 month on and 1 month off was selected from
several different possibilities. For the sake of simplicity, the cycle
was set to 1 mo, but a posteriori, this choice looks fairly reasonable
and appropriate, because the discontinuation studies have shown that
most molecular relapses occur rapidly.6,26 Dose reduction instead of
the intermittent administration was not taken into consideration, as
prolonged exposure to a low IM concentration may favor the emer-
gence and selection of resistant clones.27-29 When the study was
designed, we anticipated that some patients could lose the molecular
and CCgRs that were the most reliable surrogate markers of survival,
at least at that time. Therefore, all patients were carefully monitored,
and the protocol required that resuming the continuous schedule of
treatment was always mandatory if CCgR was lost and was advisable
if MMR was lost after the completion of the ﬁrst year of INTERIM.
With these recommendations and stringent cytogenetic and molecular
monitoring, all the patients who had lost CCgR or MMR regained
CCgR or MMR with daily IM treatment. No BCR-ABL KD point
mutation emerged, and all patients remained free from progression to
AP or BP, the ultimate goal of the study protocol.
This study cannot prove that a policy of INTERIM treatment
was better or worse than the standard policy of continuing
treatment. Furthermore, it cannot lead to the recommendation to
extend this policy either to the patients who are believed to be
ineligible for treatment discontinuation or to patients undergoing
Figure 3. Probability of maintaining INTERIM treatment. The estimated probability
of maintaining INTERIM treatment was 92% (95% CI: 86% to 98%) at 12 months and
70% (95% CI: 60% to 80%) at 48 months.
Figure 4. PFS. Estimated PFS was 100% at 12 months and 96% (95% CI: 91-100)
at 48 months. The events were 2 deaths in remission (CCgR and MMR). No
patients progressed to AP or BP.
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less stringent conventional monitoring of cytogenetic and/or molecular
response. However, these results help to open a small door to
alternative and yet unexplored policies of treatment. Currently, the
internationally shared standard policy of treatment of CML with
TKI is to continue the treatment, at the same dose, indeﬁnitely, with
the goal of ensuring survival close to that of the general population.
More recently, a more ambitious policy is gaining support with the
goal of achieving a condition of minimal residual disease such that
remission can be maintained even after treatment discontinuation.6,26
This latter policy requires sensitive molecular assessment of minimal
residual disease and foresees that the depth of the molecular response
is the best surrogate marker of outcome, but the major obstacle to its
success is the small proportion of patients who can achieve and
maintain a deep molecular response and do not relapse after treatment
discontinuation.6,26 In the patients who have been treated with IM
for years, the probability of achieving a MMR or better is high, but
the proportion of patients who maintain a MR4.0 or more for a
sufﬁciently long period is lower. There are not many data, but a recent
analysis of a multicentric series by the Gruppo Italiano Malattie
Ematologiche dell’Adulto CML WP has shown that the proportion
of patients who maintained a stable MR4.0 or better for >1 year
was ;22%.30 A similar analysis of a single center series reported
that the proportion of patients who would have ﬁt the requirements
for entering the STIM study was 21%.31 Although it is believed, and
expected, that the introduction of second-generation TKI as ﬁrst-line
treatment will mark a signiﬁcant improvement, that proportion would
hardly exceed 20% to 30%, leaving the majority of responders with a
policy of chronic treatment at the same standard schedule and dose.
In conclusion, it has been shown that in the setting of optimal
responders to IM, a 50% dose reduction of the drug results in loss
of CCgR in 17% of patients and of MMR alone in 18% of patients,
but that all patients can achieve the same level of response again by
reassuming continuous IM. What is particularly striking is that,
with a follow-up of 48 months, no patient has progressed or died
of leukemia. In elderly CML Ph1 patients carefully selected for a
stable CCgR (long lasting, ie, .2 years) and carefully monitored,
the policy of INTERIM treatment affected the markers of residual
disease, but not the clinical outcomes (OS and PFS). The results of
this study do not allow us to deﬁnitively conclude that intermittent
treatment can be offered to optimal and stable responders but opens
a window to alternative treatment policies, even in the patients for
whom a very deep molecular response cannot be achieved.
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